#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	8740	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2252	385.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1850	1850	T	487	T,A	455,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	8740	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2252	385.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1584	1584	C	472	C,G	462,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3531	449.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1644	1644	A	540	A	529	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3531	449.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2278	2278	C	506	C	488	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3531	449.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2352	2352	A	441	A	434	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	15972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3531	449.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2904	2904	C	529	C	520	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1202	folP	855	855	100.0	folP.l6.c4.ctg.1	1588	75.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1064	1066	AGC	109;111;110	A;G;C	105;110;107	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3366	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3295	101.5	1	SNP	p	S91F	1	.	.	271	273	TTC	509	511	TTC	123;124;124	T;T;C,A	122;123;119,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3366	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3295	101.5	1	SNP	p	D95G	1	.	.	283	285	GGC	521	523	GGC	124;124;124	G;G;C	120;121;119	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3366	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3295	101.5	1	SNP	p	G95N	0	.	.	283	285	GGC	521	523	GGC	124;124;124	G;G;C	120;121;119	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1030	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1364	74.9	1	SNP	p	G45D	1	.	.	133	135	GAC	433	435	GAC	139;136;135	G;A;C	136;127;133	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	484	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	938	51.5	0	.	n	.	0	A197.	DEL	197	197	A	567	567	A	98	A	96	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	509	511	AAC	119;117;117	A;A;C,A	114;107;109,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1403	1405	ATC	127;125;125	A;T;C	120;117;120	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1556	1558	GCA	129;131;133	G;C;A	123;115;117	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	1	SNP	p	S87R	0	.	.	259	261	AGT	512	514	AGT	117;117;118	A;G;T	111;113;115	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	1	SNP	p	S87W	0	.	.	259	261	AGT	512	514	AGT	117;117;118	A;G;T	111;113;115	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	1	SNP	p	S87I	0	.	.	259	261	AGT	512	514	AGT	117;117;118	A;G;T	111;113;115	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	2750	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2887	94.5	1	SNP	p	S88P	0	.	.	262	264	TCC	515	517	TCC	118;120;118	T;C;C	112;116;115	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2640	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2582	101.4	0	.	p	.	0	V89A	NONSYN	265	267	GTC	544	546	GCC	125;125;123	G;C;C	119;121;113	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2640	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2582	101.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1507	1509	GGC	147;145;142	G;G,T;C	142;140,1;133	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1255	1257	GCA	126;124;126	G;C,A;A	121;116,1;117	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1258	1260	ATC	129;131;131	A;T;C	127;125;124	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1270	1272	GTG	124;125;125	G;T;G,A	120;117;121,1	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1270	1272	GTG	124;125;125	G;T;G,A	120;117;121,1	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1774	1776	ACC	112;111;110	A;C;C	95;108;106	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1828	1830	GCG	99;100;102	G;C,G;G	94;86,3;97	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1828	1830	GCG	99;100;102	G;C,G;G	94;86,3;97	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1951	1953	GGC	74;74;73	G;G;C	72;70;71	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1960	1962	GGC	71;71;70	G;G;C	67;68;68	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	2304	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2382	95.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1978	1980	CCG	57;59;60	C;C;G,C	52;55;49,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	3360	ponA	2397	2397	99.87	ponA.l6.c30.ctg.1	3038	109.7	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1421	1423	ACG	124;123;121	A;C;G	114;116;117	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	3360	ponA	2397	2397	99.87	ponA.l6.c30.ctg.1	3038	109.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1559	1561	CTG	141;145;147	C;T;G	135;136;137	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1326	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1795	73.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	447	449	GGC	88;87;86	G;G;C	81;83;80	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1326	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1795	73.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	629	629	C	101	C	96	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1788	porB1b	1047	1047	99.04	porB1b.l6.c30.ctg.1	1483	117.8	0	.	p	.	0	A26T	NONSYN	76	78	GCC	363	365	ACC	166;166;168	A;C;C,T	161;164;166,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1788	porB1b	1047	1047	99.04	porB1b.l6.c30.ctg.1	1483	117.8	0	.	p	.	0	D41K	NONSYN	121	123	GAC	408	410	AAA	159;159;158	A;A;A	156;157;155	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1788	porB1b	1047	1047	99.04	porB1b.l6.c30.ctg.1	1483	117.8	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	645	647	AAG	139;138;140	A;A;G,C	139;137;137,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1788	porB1b	1047	1047	99.04	porB1b.l6.c30.ctg.1	1483	117.8	0	.	p	.	0	S295N	NONSYN	883	885	AGT	1170	1172	AAT	140;138;138	A;A;T	136;135;132	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1788	porB1b	1047	1047	99.04	porB1b.l6.c30.ctg.1	1483	117.8	1	SNP	p	A121D	1	.	.	361	363	GAC	648	650	GAC	140;140;139	G;A;C,A	136;135;134,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1788	porB1b	1047	1047	99.04	porB1b.l6.c30.ctg.1	1483	117.8	1	SNP	p	D121N	0	.	.	361	363	GAC	648	650	GAC	140;140;139	G;A;C,A	136;135;134,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5730	rpoB	4179	4179	99.95	rpoB.l15.c17.ctg.1	4796	118.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1912	1914	AAT	157;157;158	A;A;T	154;152;154	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	620	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1179	52.3	1	SNP	p	V57M	1	.	.	169	171	ATG	575	577	ATG	129;131;134	A;T;G	125;127;131	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
